Estados Unidos - inglês - NLM (National Library of Medicine)

proficient rx lp - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin anhydrous 875 mg - amoxicillin is indicated in the treatment of infections due to susceptible (only α -lactamase-negative) strains of the designated microorganisms in the conditions listed below: infections of the ear, nose and throat – due to streptococcus spp. (α- and β –hemolytic strains only), s. pneumoniae, staphylococcus spp., or h. influenzae. infections of the genitourinary tract – due to e. coli, p. mirabilis, or e. faecalis. infections of the skin and skin structure – due to streptococcus spp. (α- and β -hemolytic strains only), staphylococcus spp. or e. coli. infections of the lower respiratory tract – due to streptococcus spp. (α- and β –hemolytic strains only), s. pneumoniae, staphylococcus spp., or h. influenzae. gonorrhea, acute uncomplicated (ano-genital and urethral infections) – due to n. gonorrhoeae (males and females). h. pylori eradication to reduce the risk of duodenal ulcer recurrence. triple therapy: amoxicillin/clarithromycin/lansoprazole amoxicillin, in combination with clarithromycin

Estados Unidos - inglês - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin 600 mg in 5 ml - amoxicillin and clavulanate potassium for oral suspension 600 mg/42.9 mg per 5 ml is indicated for the treatment of pediatric patients with - recurrent or persistent acute otitis media due to s. pneumoniae (penicillin mics less than or equal to 2 mcg/ml), h. influenzae (including β-lactamase-producing strains), or m. catarrhalis (including β-lactamase-producing strains) characterized by the following risk factors: -antibacterial drug exposure for acute otitis media within the preceding 3 months, and either of the following: 1) age 2 years, or younger or 2) day care attendance [see microbiology (12.4)] . limitations of use acute otitis media due to s. pneumoniae alone can be treated with amoxicillin. amoxicillin and clavulanate potassium for oral suspension 600 mg/42.9 mg per 5 ml is not indicated for the treatment of acute otitis media due to s. pneumoniae with penicillin mic greater than or equal to 4 mcg/ml. therapy may be instituted prior to obtaining the results from bacteriological studies when t

Estados Unidos - inglês - NLM (National Library of Medicine)

qpharma inc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin anhydrous 875 mg -  1 indications and usage to reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin tablets, usp should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. amoxicillin tablets, usp are indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of the designated bacteria in the conditions listed below: – due to streptococcus species. (α- and β-hemolytic isolates only), streptococcus pneumoniae, staphylococcus spp., or haemophilus influenzae. – due to escherichia coli , proteus mirabilis , or enterococcus faecalis.   – due to streptococcus spp. (α- and β-hemolytic isolates only), staphyl

Estados Unidos - inglês - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin anhydrous 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin capsules, usp and other antibacterial drugs, amoxicillin capsules, usp should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.  amoxicillin capsules, usp are indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of the designated bacteria in the conditions listed below: due to streptococcus species (α- and β-hemolytic isolates only), streptococcus pneumoniae , staphylococcus spp., or haemophilus influenzae . due to escherichia coli, proteus mirabilis , or ent

Estados Unidos - inglês - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin anhydrous 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium tablets usp, amoxicillin and clavulanate potassium for oral suspension usp, and amoxicillin and clavulanate potassium tablets usp (chewable) and other antibacterial drugs, amoxicillin and clavulanate potassium tablets usp, amoxicillin and clavulanate potassium for oral suspension usp, and amoxicillin and clavulanate potassium tablets usp (chewable) should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. amoxicillin and clavulanate potassium tablets usp, amoxicillin and clavulanate potassium for oral suspension usp, and amoxicillin and clavulanate potassium tablets usp (

Bélgica - inglês - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

norbrook laboratories (ireland) ltd. - amoxicillin trihydrate - eq. amoxicillin 400 mg; clavulanic acid 100 mg - tablet - 400 mg - 100 mg - clavulanic acid 100 mg; amoxicillin trihydrate - amoxicillin - dog

Bélgica - inglês - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ceva santé animale sa-nv - amoxicillin trihydrate - eq. amoxicillin 400 mg; potassium clavulanate - eq. clavulanic acid 100 mg - chewable tablet - 400 mg - 100 mg - clavulanic acid 100 mg; amoxicillin trihydrate - amoxicillin - dog

Bélgica - inglês - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

norbrook laboratories (ireland) ltd. - amoxicillin trihydrate - eq. amoxicillin 400 mg; clavulanic acid 100 mg - tablet - 400 mg - 100 mg - clavulanic acid 100 mg; amoxicillin trihydrate - amoxicillin - dog

Malta - inglês - Malta Medicines Authority

sun pharmaceutical industries europe b.v. polarisavenue 87, 2132, jh hoofdorp, netherlands - amoxicillin trihydrate - dispersible tablet - amoxicillin trihydrate 750 mg - antibacterials for systemic use

Bélgica - inglês - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

dechra regulatory b.v. - potassium clavulanate 238,1 mg - eq. clavulanic acid 100 mg; amoxicillin trihydrate 459,2 mg - eq. amoxicillin 400 mg - tablet - 400 mg - 100 mg - amoxicillin trihydrate 459.2 mg; potassium clavulanate 238.1 mg - amoxicillin and enzyme inhibitor - dog